Skip to content

Biosurface engineering has
never been easier

Simple & Fast

Biological & Non-Biological

Controllable

01

About Us.

Kode Biotech Limited (KBL) is a private New Zealand company established in 1996 to develop, commercialise and license Kode™ Technology.

Vision: Change the surface of biotechnology
Mission: Ignite a revolution with Kode™ surface modification nanotechnology by enabling our partners to enhance existing and create next-generation products with a technology to shape life.

KBL is the holder and parent of a number of subsidiary companies that license Kode™ Technology for various sectors and uses. These subsidiaries include Kode Biotech Materials, Kode Diagnostics, Kode Implant Coatings, Kode Wound Care, Kode Veterinary and GlycoNZ, a distributor of glycoconjugate products.

Kode™ Technology has already been licensed to several large companies, and an example of a product incorporating Kode™ Technology that is already in the market is Securacell™ and cancer therapy in human clinical trials with BiolineRx.

KBL and its subsidiaries are independent companies, situated in Auckland, New Zealand.

Technical Manual – coming soon

Within the next few weeks, the first edition of the Kode Technology Illustrated Technical Manual will be available.

This eBook is free and can be directly downloaded from here or from the University of Auckland Research Space

02

Our Focus

Kode™ Technology is a multifunctional nanotechnology paint that is the easiest, fastest, most versatile, and controllable platform for temporary modification of any cell, virus, and/or surface (biological or non-biological) within a few hours enabling new and better therapeutics, diagnostics and consumer products.

Go to Kodecyte.org

The academic resource for Kode™ Technology includes journal articles, videos, MSDS, technical bulletins and FAQs.

Go to GlycoNZ

Purchase high-quality carbohydrate products, glycolipid Kode FSL constructs and glycoconjugates probes for glycobiology.

What is Kode™ Technology?

03

Our Team

We understand your requirement and provide quality works.

Management Team

Stephen Henry

Founder & CEO

Nicolai Bovin

CSO

Chris Trent

COO

Stephen Parker

CIPO

Board of Directors

Stephen Henry

Founder & CEO

David Ross

Chairman

Julia Chambers

Director

Selwyn Yorke

Director

04

FSL Constructs

All natural biological surfaces (e.g. cells, viruses, microbes, and organisms) exhibit a large range of complex biological molecules with functions ranging from structural integrity and basic biological processes to key modulators of chemical communications and other functions such as protection, adhesion, infectivity, apoptosis, etc.

The ability to precisely control, manipulate and mimic biological surfaces, and alter their properties is potentially one of the most important areas in biotechnology. Modified natural and/or synthetic biosurfaces have applications in diagnostics, biotherapeutics, tissue engineering, transplantation, immunology, oncology, drug targeting and release, biosensors, bioelectronics and research & development.

Kode™ “nanotechnology paint” of functional head-spacer-lipid (FSL) constructs offer unparalleled flexibility for mimicking biosurface components and attaching novel function(s) to intact biological and synthetic surfaces alike.
05

Newsroom

Kode Biotech in the media
Covid 19 coronavirus: Kiwi tech could offer low-cost immunity test

By Jamie Morton Original Article Kiwi-developed technology – using “synthetic paint” to coat the out…

Filter research wows at Falling Walls

Third place Berlin Falling Walls Lab Finale 2018 Original Article Auckland University of Technology&…

2017 Pickering Medal: Painting cells and surfaces with bio-paints for widespread beneficial use

Original Article Professor Stephen Henry has been awarded the Pickering Medal by the Royal Society T…

The cure for cancer may be closer than we think, all thanks to a Kiwi invention

Simon Pound | Business is Boring boss | The Spinoff article Business is Boring is a weekly podcast s…

2017 finalists showcase research driving innovation

Hamilton, NZ, 18 May 2017 – Twelve finalists have been selected for the fifth annual KiwiNet Researc…

Alumni @ JLABS – Kode Biotech

Area of focus: Our focus is to get Kode Technology licensed broadly as a core component that enables…

Kiwi-made technology could cure cancer

Original article by Lucy Warhurst, Newshub A New Zealand-made technology behind a promising bre…

BiolineRx acquires Agalimmune, a licensee using Kode Technology as an immuno-oncotherapeutic

BioLineRx Buys U.K. Cancer Immunotherapeutics Firm Agalimmune GEN News Highlights Original Article B…

CEO, Stephen Henry presents at TEDxChristchurch

Technology that transforms your cells | Stephen Henry | TEDxChristchurch What if you could make your…

Infection fighter has global potential

Surgical implants can be life-changing. Millions of people across the globe have had their mobility …

Kode Biotech, winner of the Supreme New Zealand Innovator award

By HENRY OLIVER, idealog NZ Innovator Awards Kode Biotech wins the Supreme NZ Innovator Award 2015 f…

Cure for cancer just around the corner

Newshub Stephen Henry took home the prize of Supreme Innovator award at the NZ Innovators Awards. Hi…

£21m deal: UK firm licenses cancer treatment technology from AUT’s Kode Biotech

By Chris Keall Under the terms of the agreement, Kode may receive up to £21 million in development a…

Two therapeutic-use agreements signed

Kode Biotech Limited concluded two therapeutic agreements. The first, with a publicly listed French …

Ten ways to use New Zealand’s biotech innovation: Kode Technology

Original Article by Jamie Morton, Science Reporter, NZ Herald Biological “invisible ink”…

06

Get in Touch

Have a question? Let us know and we’ll be in touch
Here for you

Contact us 24/7.
We are here for your support.

Ordering

Product catalogue and pricing on glyconz.com

Where to find us

19 Mount Street, Scott Laboratory Building, Auckland 1010, New Zealand